Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 13/20 | 0.46 |
| ▸ | THRB | P10828 | 13/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367322 | 0.87 | THRA (0.62) | THRATHRBCYP3A4CYP2C19TPMT | |
| SCHEMBL5367327 | 0.87 | THRA (0.62) | THRATHRBCYP3A4CYP2C19TPMT | |
| SCHEMBL5351679 | 0.86 | THRA (0.43) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL12312830 | 0.84 | THRA (0.50) | THRATHRBCYP3A4CYP2C19TPMT | |
| SCHEMBL5351673 | 0.84 | THRA (0.43) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5964697 | 0.82 | THRA (0.49) | THRATHRBCYP2C19 | |
| SCHEMBL5964528 | 0.82 | THRA (0.49) | THRATHRB | |
| SCHEMBL5282266 | 0.81 | THRA (0.47) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5351674 | 0.79 | THRA (0.48) | THRATHRBCYP3A4CYP2C19 | |
| SCHEMBL5354531 | 0.79 | CYP3A4 (0.40) | THRATHRBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153997-B2 | Benzamide derivatives as thyroid receptor ligands | KARO BIO AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060135614-A1 | Novel compounds | NORIN, THOMAS ANDERS WILSON (SE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135614-A1 | Novel compounds | THRB, TSHR, THRA | THRA 3/4885THRB 1/4885CYP3A4 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.